Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
Go back to Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting| (NASDAQ: RVMD) | Delayed: 191.13 +1.36 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $189.77 | 52 Week High | $ | |||
| Open | $190.05 | 52 Week Low | $ | |||
| Day High | $193.83 | P/E | N/A | |||
| Day Low | $190.04 | EPS | $ | |||
| Volume | 1,610,184 | |||||
